# US 2026/0232704 A1 · Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232704 A1
- Document ID: US20260232704A1
- Status: Published application
- Kind: A1
- Application number: 19/639,112
- Filed: 2026-04-03
- Published: 2026-08-13
- Earliest claimed: 2019-03-07
- Assignees: Arbormentis LLC
- Applicants: Arbormentis LLC
- Inventors: Paolo L. Manfredi; Charles E. Inturrisi; Sara De Martin; Andrea Mattarei; Maurizio Rolando; Giovanni Giordano; Claudia Lodovichi; Paola Brun; Marco Pappagallo; Franco Folli; Andrea Alimonti; Jacopo Sgrignani; Andrea Cavalli
- Web page: https://patentgrep.com/patent/US20260232704A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- C07D 471/04: Ortho-condensed systems
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/30: Zinc; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/10: for accommodation disorders, e.g. myopia
- C07C 215/52: linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07C 217/60: linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 209/16: Tryptamines
- C07D 457/06: Lysergic acid amides
- C07D 471/06: Peri-condensed systems
- C07D 471/08: Bridged systems
- C07D 471/18: Bridged systems
- C07D 471/22: in which the condensed systems contains four or more hetero rings
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compositions and methods of use comprising serotonin (5-HT) receptor agonists and NMDAR modulating substances, including especially certain substances classified as 5-HT2A agonists presently disclosed to exert NMDAR modulating effects, administered as modulators of neural plasticity, at non-psychedelic/psychotomimetic dosages, posology and formulations, for treatment of diseases and conditions and for improving functions (neuroplastogens).

## Claims

### Claim 1

A compound comprising a structural analogue to psilocin, norpsilocin, psilocybin, baeocystin, norbaeocystin or N,N-dimethyltryptamine, according to formula I:
wherein
R1 and R2 are, independently, hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl (independently or ring close with the nitrogen), C3-C8 cycloalkenyl (independently or ring close with the nitrogen), aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate;
R3 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R3 is selected from the group consisting of halogen, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryloxy, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, and nitrate;
R4 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, any of which are optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R4 is selected from the group consisting of alkyl ester, formyl, hydroxy, arylamido, alkylamido, alkylcarbamoyl, arylcarbamoyl, amino, alkylsulfonyl, and alkylamino;
R5 represents 1-3 substituents selected from the group consisting of hydrogen, deuterium, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate;
R6 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl any of which are optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R6 is selected from the group consisting of halogen, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryloxy, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, nitrate, —OP(O)(OH)2, —OC(O)R7, —OSO2OH, —OC(O)NHR7, —OC(O)NR7R8 and —SONH; and
n is 1 to 5.

### Claim 2

A method for treating diseases and conditions or improving functions in patients or subjects, the method comprising:
administering a compound to a subject;
wherein the compound is chosen from psilocin, norpsilocin, psilocybin, baeocystin, N, N-dimethyltryptamine, a structural analogue of psilocin, a structural analogue of norpsilocin, a structural analogue of psilocybin, a structural analogue of baeocystin, a structural analogue of norbaeocystin, and a structural analogue of N, N-dimethyltryptamine;
wherein the compound is of formula I:
wherein
R1 and R2 are, independently, hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl (independently or ring close with the nitrogen), C3-C8 cycloalkenyl (independently or ring close with the nitrogen), aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate;
R3 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R3 is selected from the group consisting of halogen, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryloxy, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, and nitrate;
R4 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, any of which are optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R4 is selected from the group consisting of alkyl ester, formyl, hydroxy, arylamido, alkylamido, alkylcarbamoyl, arylcarbamoyl, amino, alkylsulfonyl, and alkylamino;
R5 represents 1-3 substituents selected from the group consisting of hydrogen, deuterium, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate;
R6 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl any of which are optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R6 is selected from the group consisting of halogen, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryloxy, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, nitrate, —OP(O)(OH)2, —OC(O)R7, —OSO2OH, —OC(O)NHR7, —OC(O)NR7R8 and—SONH; and
n is 1 to 5; and
wherein the compound is administered at doses, dosages, posology, or formulations devoid of clinically meaningful psychedelic or psychotomimetic actions or effects.

### Claim 3 (depends on 2)

The method of claim 2, wherein said clinical effects are comparable to those exerted by human plasma psilocin Cmax of 2 ng/ml or less or 5-HT2A human CNS receptor occupancy of 40% or less.

### Claim 4 (depends on 2)

The method of claim 2, wherein said clinical effects are comparable to those exerted by human plasma psilocin Cmax of 1 ng/ml or less or 5-HT2A human CNS receptor occupancy of 30% or less.

### Claim 5 (depends on 2)

The method of claim 2, wherein said PD effects are comparable to those exerted by human plasma psilocin Tmax in excess of 120 minutes.

### Claim 6 (depends on 2)

The method of claim 2, wherein said PD effects are comparable to those exerted by human plasma psilocin Tmax in excess of 180 minutes.

### Claim 7 (depends on 2)

The method of claim 2, wherein the administering of the compound occurs under conditions that may modulate NMDARs and their subunits in addition to modulate 5-HT2A receptors.

### Claim 8 (depends on 2)

The method of claim 2, wherein the administering of the compound may provide excitotoxicity protection.

### Claim 9 (depends on 2)

The method of claim 2, wherein the administering of the compound may modulate neurogenesis.

### Claim 10 (depends on 2)

The method of claim 2, wherein the administering of the compound occurs under conditions effective for the substance to exert neuroplastogen effects, including modulation of neural plasticity.

### Claim 11 (depends on 2)

The method of claim 2, wherein the administration of the compound is repeated over days or months or is chronic.

### Claim 12 (depends on 2)

The method of claim 2, wherein the administration of the compound is intermittent and occurs every second day, every third day or every other week or every 2 weeks or every other month.

### Claim 13

A method for treating diseases and conditions or improving functions in patients or subjects, the method comprising:
administering a 5-HT2A agonist substance to a subject;
wherein the 5-HT2A agonist substance is chosen from psilocin,
norpsilocin, psilocybin, baeocystin, N,N-dimethyltryptamine, a structural analogue of psilocin, a structural analogue of norpsilocin, a structural analogue of psilocybin, a structural analogue of baeocystin, a structural analogue of norbaeocystin, and a structural analogue of N,N-dimethyltryptamine;
wherein the compound is of formula I:
wherein
R1 and R2 are, independently, hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C5 alkynyl, C3-C8 cycloalkyl (independently or ring close with the nitrogen), C3-C8 cycloalkenyl (independently or ring close with the nitrogen), aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate;
R3 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R3 is selected from the group consisting of halogen, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryloxy, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, and nitrate;
R4 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, any of which are optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R4 is selected from the group consisting of alkyl ester, formyl, hydroxy, arylamido, alkylamido, alkylcarbamoyl, arylcarbamoyl, amino, alkylsulfonyl, and alkylamino;
R5 represents 1-3 substituents selected from the group consisting of hydrogen, deuterium, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl, optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate;
R6 is hydrogen, deuterium, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, aryl or heterocyclyl any of which are optionally substituted at one or more positions by deuterium, halogen, alkyl, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryl, aryloxy, heterocyclyl, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, or nitrate; or R6 is selected from the group consisting of halogen, alkyl ester, hydroxy, alkoxy, carboxy, formyl, aryloxy, amino, alkylamino, arylamido, alkylamido, thiol, thioalkyl, thioaryl, alkylsulfonyl, alkylcarbamoyl, arylcarbamoyl, nitro, cyano, nitrate, —OP(O)(OH)2, —OC(O)R7, —OSO2OH, —OC(O)NHR7, —OC(O)NR7R8 and—SONH; and
n is 1 to 5; and
wherein the compound is administered at doses, dosages, posology, or formulations devoid of clinically meaningful psychedelic or psychotomimetic actions or effects.

### Claim 14 (depends on 13)

The method of claim 13, wherein said clinical effects are comparable to those exerted by human plasma psilocin Cmax of 2 ng/ml or less or 5-HT2A human CNS receptor occupancy of 40% or less.

### Claim 15 (depends on 13)

The method of claim 13, wherein said clinical effects are comparable to those exerted by human plasma psilocin Cmax of 1 ng/ml or less or 5-HT2A human CNS receptor occupancy of 30% or less

### Claim 16 (depends on 13)

The method of claim 13, wherein said PD effects are comparable to those exerted by human plasma psilocin Tmax in excess of 120 minutes.

### Claim 17 (depends on 13)

The method of claim 13, wherein said PD effects are comparable to those exerted by human plasma psilocin Tmax in excess of 180 minutes.

### Claim 18 (depends on 13)

The method of claim 13, wherein the administering of the 5-HT2A agonist substance occurs under conditions that may modulate NMDARs and their subunits in addition to modulate 5-HT2A receptors.

### Claim 19 (depends on 13)

The method of claim 13, wherein the administering of the 5-HT2A agonist substance may provide excitotoxicity protection.

### Claim 20 (depends on 13)

The method of claim 13, wherein the administering of the 5-HT2A agonist substance may modulate neurogenesis.

### Claim 21 (depends on 13)

The method of claim 13, wherein the administering of the 5-HT2A agonist substance occurs under conditions effective for the substance to exert neuroplastogen effects, including modulation of neural plasticity.

### Claim 22 (depends on 13)

The method of claim 13, wherein the administration of the 5-HT2A agonist substance is repeated over days or months or is chronic.

### Claim 23 (depends on 13)

The method of claim 13, wherein the administration of the 5-HT2A agonist substance is intermittent and occurs every second day, every third day or every other week or every 2 weeks or every other month.

### Claim 24 (depends on 13)

The method of claim 13, wherein the method includes the treatment of the metabolic syndrome and its complications.

### Claim 25 (depends on 13)

The method of claim 13, wherein the method includes the treatment of impaired glucose tolerance, diabetes and their complication.

### Claim 26 (depends on 13)

The method of claim 13, wherein the method includes the treatment of NAFL, NAFLD, NASH and their complications.

### Claim 27 (depends on 13)

The method of claim 13, wherein the method includes the treatment of obesity and its complications.

### Claim 28 (depends on 13)

The method of claim 13, wherein the method includes the treatment of vision impairment, visual loss, macular degeneration, and retinopathies.

### Claim 29 (depends on 13)

The method of claim 13, wherein the method includes the treatment of Alzheimer's disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, mild cognitive impairment associated with aging and with chronic disease and its treatment, cognitive impairment associated with chemotherapy, cognitive impairment associated with immunotherapy, cognitive impairment associated with radiotherapy, Parkinson's disease, Parkinsonian related disorders, Parkinson dementia; disorders associated with accumulation of beta amyloid protein, cerebrovascular amyloid angiopathy, posterior cortical atrophy; disorders associated with accumulation or disruption of tau protein and its metabolites; frontotemporal dementia and its variants, frontal variant, primary progressive aphasias; semantic dementia; progressive non fluent aphasia, corticobasal degeneration, supranuclear palsy; epilepsy; NS trauma; NS infections; NS inflammation, inflammation from autoimmune disorders, NMDAR encephalitis, cytopathology from toxins, cytopathology from microbial toxins, cytopathology from heavy metals, cytopathology from pesticides; stroke; multiple sclerosis; Huntington's disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina, glaucoma, diabetic retinopathy, age-related macular degeneration; amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder, attention deficit disorders; restless leg syndrome; Tourette's syndrome; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system, eating disorders, anorexia nervosa (“AN”), bulimia nervosa (“BN”); binge eating disorder (“BED”), trichotillomania, dermotillomania, nail biting; migraine; fibromyalgia; peripheral neuropathy of any etiology; a decline, impairment, or abnormality in cognitive abilities, a decline, impairment, or abnormality in executive function, a decline, impairment, or abnormality in attention, a decline, impairment, or abnormality in cognitive speed, a decline, impairment, or abnormality in memory, a decline, impairment, or abnormality in language functions, a decline, impairment, or abnormality in orientation in space and time, praxis, a decline, impairment, or abnormality in ability to perform actions, a decline, impairment, or abnormality in ability to recognize faces or objects, a decline, impairment, or abnormality in concentration, a decline, impairment, or abnormality in alertness; abnormal movements including akathisia, bradykinesia, tics, myoclonus, dyskinesias, dyskinesias relate to Huntington's disease, levodopa induced dyskinesias, neuroleptic induced dyskinesias, dystonias, tremors, essential tremor, restless leg syndrome; parasomnias, insomnia, disturbed sleep pattern; psychosis; delirium; agitation; headache; motor weakness, spasticity, impaired physical endurance; sensory impairment, impairment of vision and visual field defects, smell, taste, hearing and balance, dysesthesias; dysautonomia; ataxia, impairment of balance or coordination, tinnitus, neuro-otological and eye movement impairments, neurological symptoms of alcohol withdrawal, delirium, headache, tremors, hallucinations, and hypertension.

### Claim 30 (depends on 13)

The method of claim 13, wherein the method includes the treatment of psychiatric diseases selected form the group consisting of Schizophrenia spectrum and other psychotic disorders, Bipolar and related disorders, Depressive disorders, Anxiety disorders, Obsessive-compulsive and related disorders, Trauma- and stressor-related disorders, Dissociative disorders, Somatic symptom and related disorders, Feeding and eating disorders, Elimination disorders, Sleep-wake disorders, Sexual dysfunctions, Gender dysphoria, Disruptive disorders, impulse-control disorders, conduct disorders, Substance-related and addictive disorders, Neurocognitive disorders, Personality disorders, and Paraphilic disorders.

### Claim 31 (depends on 13)

The method of claim 13, wherein the method includes the treatment of systemic inflammatory states and autoimmune disorders.

### Claim 32 (depends on 13)

The method of claim 13, wherein the method includes the treatment of aging, senescence and associated deficits, or osteoporosis.

### Claim 33 (depends on 13)

The method of claim 13, wherein the method includes the treatment of dry eye syndrome.

### Claim 34 (depends on 13)

The method of claim 13, wherein the method includes the treatment of restless leg syndrome.

### Claim 35 (depends on 13)

The method of claim 13, wherein the function is chosen from visual, auditory, sense of balance, olfactory, gustatory.

### Claim 36 (depends on 13)

The method of claim 13, where the compound is a first compound and is in combination with at least a second compound, the first compound being administered at doses of 0.01-24 mg, and the second compound being an open-channel low-affinity uncompetitive NMDAR antagonist-selected from the group comprising dextromethorphan, dextromethadone, ketamine and its isomers, memantine, amantadine, and noribogaine, and wherein the second compound is administered at doses of 0.01-50 mg.

### Claim 37 (depends on 13)

The method of claim 13, further comprising administration of the 5-HT2A agonist substance in combination with magnesium and or zinc and or lithium and salts thereof.

### Claim 38 (depends on 2)

The method of claim 2, wherein the substance is coated with an emetic drug to lower the abuse potential of the substance.

### Claim 39 (depends on 2)

The method of claim 2, wherein the administering of substance is performed orally, buccally, sublingually, rectally, vaginally, nasally, via aerosol, trans-dermally, trans-mucosal, parenterally, epidurally, intrathecally, intra-auricularly, intraocularly, via implanted depot formulations, or topically.

### Claim 40 (depends on 2)

The method of claim 2, wherein the method includes the treatment of the metabolic syndrome and its complications.

### Claim 41 (depends on 2)

The method of claim 2, wherein the method includes the treatment of impaired glucose tolerance, diabetes and their complication.

### Claim 42 (depends on 2)

The method of claim 2, wherein the method includes the treatment of NAFL, NAFLD, NASH and their complications.

### Claim 43 (depends on 2)

The method of claim 2, wherein the method includes the treatment of obesity and its complications.

### Claim 44 (depends on 2)

The method of claim 2, wherein the method includes the treatment of vision impairment, visual loss, macular degeneration, or retinopathies.

### Claim 45 (depends on 2)

The method of claim 2, wherein the method includes the treatment of Alzheimer's disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, mild cognitive impairment associated with aging and with chronic disease and its treatment, cognitive impairment associated with chemotherapy, cognitive impairment associated with immunotherapy, cognitive impairment associated with radiotherapy, Parkinson's disease, Parkinsonian related disorders, Parkinson dementia; disorders associated with accumulation of beta amyloid protein, cerebrovascular amyloid angiopathy, posterior cortical atrophy; disorders associated with accumulation or disruption of tau protein and its metabolites; frontotemporal dementia and its variants, frontal variant, primary progressive aphasias; semantic dementia; progressive non fluent aphasia, corticobasal degeneration, supranuclear palsy; epilepsy; NS trauma; NS infections; NS inflammation, inflammation from autoimmune disorders, NMDAR encephalitis, cytopathology from toxins, cytopathology from microbial toxins, cytopathology from heavy metals, cytopathology from pesticides; stroke; multiple sclerosis; Huntington's disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina, glaucoma, diabetic retinopathy, and age-related macular degeneration; amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder, attention deficit disorders; restless leg syndrome; Tourette's syndrome; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system, eating disorders, anorexia nervosa (“AN”), bulimia nervosa (“BN”); binge eating disorder (“BED”), trichotillomania, dermotillomania, nail biting; migraine; fibromyalgia; and peripheral neuropathy of any etiology; a decline, impairment, or abnormality in cognitive abilities, a decline, impairment, or abnormality in executive function, a decline, impairment, or abnormality in attention, a decline, impairment, or abnormality in cognitive speed, a decline, impairment, or abnormality in memory, a decline, impairment, or abnormality in language functions, a decline, impairment, or abnormality in orientation in space and time, praxis, a decline, impairment, or abnormality in ability to perform actions, a decline, impairment, or abnormality in ability to recognize faces or objects, a decline, impairment, or abnormality in concentration, a decline, impairment, or abnormality in alertness; abnormal movements including akathisia, bradykinesia, tics, myoclonus, dyskinesias, dyskinesias relate to Huntington's disease, levodopa induced dyskinesias, neuroleptic induced dyskinesias, dystonias, tremors, essential tremor, restless leg syndrome; parasomnias, insomnia, disturbed sleep pattern; psychosis; delirium; agitation; headache; motor weakness, spasticity, impaired physical endurance; sensory impairment, impairment of vision and visual field defects, smell, taste, hearing and balance, dysesthesias; dysautonomia; ataxia, impairment of balance or coordination, tinnitus, neuro-otological and eye movement impairments, neurological symptoms of alcohol withdrawal, delirium, headache, tremors, hallucinations, and hypertension.

### Claim 46 (depends on 2)

The method of claim 2, wherein the method includes the treatment of systemic inflammatory states and autoimmune disorders.

### Claim 47 (depends on 2)

The method of claim 2, wherein the method includes the treatment of aging, senescence and associated deficits, or osteoporosis.

### Claim 48 (depends on 2)

The method of claim 2, wherein the method includes the treatment of dry eye syndrome.

### Claim 49 (depends on 2)

The method of claim 2, wherein the method includes the treatment of restless leg syndrome.

### Claim 50 (depends on 2)

The method of claim 2, wherein the function is chosen from visual, auditory, sense of balance, olfactory, gustatory.

### Claim 51 (depends on 2)

The method of claim 2, where the compound is a first compound and is in combination with at least a second compound,
the first compound being administered at doses of 0.01-24 mg; and
the second compound being an open-channel low-affinity uncompetitive NMDAR antagonist selected from the group consisting of dextromethorphan, dextromethadone, ketamine, an isomer of ketamine, memantine, amantadine, and noribogaine, wherein the second compound is administered at doses of 0.01-50 mg.

### Claim 52 (depends on 2)

The method of claim 2, further comprising administration of the compound in combination with magnesium and or zinc and or lithium and salts thereof.

### Claim 53 (depends on 2)

The method of claim 2, wherein the compound has clinical effects of those exerted by human plasma psilocin Cmax of 4 ng/ml or less, or human 5-HT2A CNS receptor occupancy of 50% or less, or PD effects of those exerted by human plasma psilocin Tmax in excess of 60 minutes.

### Claim 54 (depends on 13)

The method of claim 13, wherein the 5-HT2A agonist has clinical effects of those exerted by human plasma psilocin Cmax of 4 ng/ml or less, or human 5-HT2A CNS receptor occupancy of 50% or less, or PD effects of those exerted by human plasma psilocin Tmax in excess of 60 minutes.
